Does GNPX pay dividends?

Genprex Inc (GNPX) does not currently pay a regular dividend.

What is GNPX's market cap?

Genprex Inc (GNPX) has a market capitalization of $3.01M with a current stock price of $3.71.

Genprex Inc (GNPX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.71

+0.04 (+1.09%)

Market Cap: $3.01M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

40%(12/30)

Avg Surprise

-328.97%

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26	$-9.40	N/A	-	N/A	Beat	-	-	-11.0%
Mar 31, 2026Mar 26	$-14.12	N/A	-	N/A	Beat	-	-	-647.3%
Dec 31, 2025Dec 25	$-25.33	$0.83	$0.83 - $0.83	-3152.22%	Miss	0	1 0 30d	-5872.0%
Sep 30, 2025Sep 25	$-5.00	$-0.65	$-0.65 - $-0.65	-669.23%	Miss	0	1 0 30d	+99.6%
Jun 30, 2025Jun 25	$-8.47	$-0.74	$-0.74 - $-0.74	-1044.59%	Miss	1	1 0 30d	+99.7%
Mar 31, 2025Mar 25	$2.58	$-0.39	$-0.39 - $-0.39	+761.54%	Beat	1	1 0 30d	+100.1%
Dec 31, 2024Dec 24	$-0.42	$-0.39	$-0.39 - $-0.39	-8.77%	Miss	1	1 0 30d	+89.3%
Sep 30, 2024Sep 24	$-1353.00	N/A	-	+54.95%	Beat	2	No revisions (30d)	-1040669.2%
Jun 30, 2024Jun 24	$-3300.00	$-2530.00	$-2530.00 - $-2530.00	-30.43%	Miss	1	No revisions (30d)	-2199900.0%
Mar 31, 2024Mar 24	$-4059.00	$-2794.00	$-2794.00 - $-2794.00	-45.28%	Miss	1	No revisions (30d)	-2136215.8%
Dec 31, 2023Dec 23	$-3.96	$-3.93	$-5.60 - $-0.80	-0.76%	Miss	3	No revisions (30d)	+99.9%
Sep 30, 2023Sep 23	$-0.13	$-0.11	$-0.11 - $-0.11	-18.18%	Miss	1	No revisions (30d)	+100.0%
Jun 30, 2023Jun 23	$-0.15	$-0.12	$-0.12 - $-0.12	-25.00%	Miss	1	No revisions (30d)	+100.0%
Mar 31, 2023Mar 23	$-0.19	$-0.12	$-0.12 - $-0.12	-58.33%	Miss	1	No revisions (30d)	+100.0%
Dec 31, 2022Dec 22	$-6600.01	$-6600.01	$-6600.02 - $-6600.00	+0.00%	Beat	2	No revisions (30d)	-5499908.3%
Sep 30, 2022Sep 22	$-5720.01	$-5280.01	$-5280.01 - $-5280.01	-8.33%	Miss	1	No revisions (30d)	-85.7%
Jun 30, 2022Jun 22	$-4840.00	$-5280.01	$-5280.01 - $-5280.01	+8.33%	Beat	1	No revisions (30d)	-37.5%
Mar 31, 2022Mar 22	$-5280.01	$-5280.01	$-5280.01 - $-5280.01	+0.00%	Beat	1	No revisions (30d)	+14.3%
Dec 31, 2021Dec 21	$-0.12	$-0.09	$-0.11 - $-0.08	-33.33%	Miss	2	No revisions (30d)	+14.3%
Sep 30, 2021Sep 21	$-3080.00	$-4840.00	$-4840.00 - $-4840.00	+36.36%	Beat	0	No revisions (30d)	+0.0%
Jun 30, 2021Jun 21	$-3520.00	$-5720.01	$-5720.01 - $-5720.01	+38.46%	Beat	1	No revisions (30d)	+33.3%
Mar 31, 2021Mar 21	$-6160.01	$-5280.01	$-5280.01 - $-5280.01	-16.67%	Miss	1	No revisions (30d)	+30.0%
Dec 31, 2020Dec 20	$-0.14	$-0.28	$-0.28 - $-0.28	+50.00%	Beat	1	No revisions (30d)	+6.7%
Sep 30, 2020Sep 20	$-3080.00	N/A	-	+66.67%	Beat	1	No revisions (30d)	-1283233.3%
Jun 30, 2020Jun 20	$-5280.01	$-8360.01	$-8360.07 - $-8359.95	+36.84%	Beat	2	No revisions (30d)	+14.3%
Mar 31, 2020Mar 20	$-8800.01	$-3520.00	-	-150.00%	Miss	-	-	-109900.1%
Sep 30, 2019Sep 19	$-0.15	$-0.22	$-0.22 - $-0.22	+31.82%	Beat	0	No revisions (30d)	+100.0%
Jun 30, 2019Jun 19	$-0.24	$-0.21	$-0.21 - $-0.21	-14.29%	Miss	1	No revisions (30d)	+22.6%
Mar 31, 2019Mar 19	$-6160.01	$-9240.01	$-9240.04 - $-9239.98	+33.33%	Beat	3	No revisions (30d)	-12319920.0%
Dec 31, 2018Dec 18	$-8.00	$-0.14	$-0.15 - $-0.12	-5614.29%	Miss	2	No revisions (30d)	-11328.6%
Sep 30, 2018Sep 18	$-6600.01	$-5720.01	$-5720.01 - $-5720.01	-15.38%	Miss	0	No revisions (30d)	-13199920.0%
Jun 30, 2018Jun 18	$-0.31	$-0.17	-	-82.35%	Miss	-	-	-
Mar 31, 2018Mar 18	$-0.05	N/A	-	N/A	Beat	-	-	-
Sep 30, 2017Sep 17	$-0.07	$0.00	-	N/A	Miss	-	-	-
Jun 30, 2017Jun 17	$-0.05	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.07	EV/EBITDA	0.18x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-203.90%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	6.77x	Quick Ratio	6.77x
Trading Statistics
Beta	-0.89	Avg Volume	460.60K
52-Week High	$1210.00	52-Week Low	$3.57

Technical Indicators Dashboard

Moving Averages

SMA 10$3.88

SMA 20$4.17

SMA 50$7.53

SMA 200$32.70

EMA 10$3.95

EMA 20$4.61

EMA 50$7.91

EMA 200$57.13

MACD

Line: -1.09Signal: -1.30Hist: 0.20

ADX

ADX: 13.5+DI: 7.5-DI: 8.2

Aroon & PSAR

Aroon Up4.0

Aroon Down92.0

PSAR$8.74

Bollinger Bands

Upper Band$4.86

Lower Band$3.48

%B Position3315%(Upper)

Band Width0.17

RSI (14-Day)

Oversold

28.3

Momentum Oscillators

Stoch %K5.6

Stoch %D6.6

Williams %R-91.6

ROC (10d)-17.1%

Momentum-0.77

CCI (20d)-119.9

MFI (14d)6.9

Volatility Measures

ATR (14d)$1.53(41.3%)

StdDev (20d)0.35

Hist Vol81.4%(High)

Volume Flow

VWAP$3.73

OBV934.0M

AD Line13607.7B

CMF (20d)-0.540

Volume Metrics

Avg Vol (20d)342.7K

Vol Ratio0.1x(Low)

VWMA (20d)$4.07

Pivot Points

R3$3.86

R2$3.80

R1$3.74

Pivot Point$3.68

S1$3.62

S2$3.56

S3$3.50

Advanced Oscillators

TSI-43.85

Ultimate Osc28.3

KST-442.09

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$-2,208	$0
Cost of Revenue	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	N/A	$0
Gross Profit	$0	$0	N/A	$0	$0	$0	N/A	$0	$0	$0	$-2,208	$0

Operating Expenses	$4.48M	$4.49M	$3.52M	$3.35M	$4.68M	$3.97M	$4.34M	$4.32M	$6.52M	$6.00M	$5.97M	$7.79M
R&D	$2.68M	$2.75M	$2.20M	$2.19M	$2.50M	$2.54M	$2.84M	$2.76M	$1.67M	$3.27M	$3.71M	$4.62M
SG&A	$1.80M	$1.75M	$1.32M	$1.15M	$2.18M	$1.43M	$1.50M	$1.57M	$4.85M	$2.72M	$2.25M	$3.17M
Operating Income	$-4,483,984	$-4,494,184	$-3,518,630	$-3,345,913	$-4,681,784	$-3,969,292	$-4,335,730	$-4,323,438	$-6,518,282	$-5,996,717	$-5,968,062	$-7,786,327

Interest Income	$-525	$0	$0	$2,405	$2	$0	$0	$8,080	$23,057	$27,713	$39,697	$51,391
Interest Expense	$525	$0	$298,481	$453,327	$0	$80	$57,736	$0	$0	$0	$0	$0
Income Before Tax	$-4,484,509	$-4,493,643	$-3,817,111	$-3,799,240	$-4,681,782	$-3,969,372	$-4,393,466	$-4,315,987	$-6,495,845	$-5,968,869	$-5,927,043	$-7,748,243
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-4,447,219	$-4,461,895	$-3,790,211	$-3,799,240	$-4,674,901	$-3,964,601	$-4,330,462	$-4,315,987	$-6,495,845	$-5,968,869	$-5,929,251	$-7,748,243

EBITDA	$-4,483,984	$-4,493,643	$-3,803,054	$-3,801,645	$-4,681,784	$-3,969,372	$-4,334,153	$-4,322,795	$-6,516,614	$-5,993,912	$-5,964,636	$-7,795,909
EBIT	$-4,483,984	$-4,493,643	$-3,803,054	$-3,801,645	$-4,681,784	$-3,969,372	$-4,334,616	$-4,324,067	$-6,518,902	$-5,996,582	$-5,968,062	$-7,799,634

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about GNPX

News

Form 8K Genprex Inc For: 18 August By Investing.com

This article announces that Genprex Inc. filed a Form 8K on August 18, 2026. The filing is brief and primarily serves as a notification of the SEC document's availability, with no further details provided in the immediate text. The article also includes various market data and other news items.

Investing.com South Africa•Aug 18, 2026 12:11 PM8/18/26•

Neutral

Genprex is scaling a diabetes therapy designed to deliver two genes to the pancreas

Genprex has partnered with a leading U.S.-based Contract Development and Manufacturing Organization (CDMO) to scale up manufacturing of its AAV-based diabetes gene therapy. This collaboration aims to transition the therapy from research-grade to clinical and commercial-ready production, ensuring cGMP compliance for IND-enabling preclinical studies and future clinical trials. The gene therapy, which delivers Pdx1 and MafA genes to the pancreas, is designed to convert alpha cells into insulin-producing beta-like cells for Type 1 diabetes and rejuvenate exhausted beta cells for Type 2 diabetes.

Stock Titan•Aug 18, 2026 11:11 AM8/18/26•

Somewhat-Bearish

Genprex partners with CDMO for diabetes gene therapy manufacturing

Genprex Inc. announced a partnership with a U.S.-based contract development and manufacturing organization (CDMO) to scale up production of its diabetes gene therapy program. This collaboration aims to transition the therapeutic candidate from research-grade to clinical and commercial-ready output, including manufacturing for preclinical studies and future clinical trials. The gene therapy involves delivering Pdx1 and MafA genes into the pancreas using an AAV vector, and the company is also exploring non-viral lipid nanoparticle delivery systems.

Investing.com•Aug 18, 2026 11:11 AM8/18/26•

Bullish

Genpre announces CDMO partnership to scale AAV diabetes gene therapy toward cGMP clinical supply

Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. CDMO to scale up its AAV-based diabetes gene therapy. This partnership aims to transition the therapy from research-grade to cGMP clinical/commercial-ready manufacturing, supporting IND-enabling preclinical studies and future clinical trials. The plan includes process optimization, bioreactor scale-up, and potency assay development to ensure dose availability and regulatory compliance.

TradingView•Aug 18, 2026 11:11 AM8/18/26•

Bullish

Genprex advances AAV diabetes gene therapy manufacturing

Genprex announced a U.S. CDMO agreement to scale up manufacturing for its AAV-based diabetes gene therapy, moving towards cGMP-compliant clinical and commercial production. Preclinical data in mice and primates demonstrated the therapy's ability to normalize glucose, reduce insulin needs, and rejuvenate beta cells for both Type 1 and Type 2 diabetes. This manufacturing scale-up is crucial for advancing the gene therapy into human clinical trials and eventual commercialization.

TipRanks•Aug 18, 2026 11:11 AM8/18/26•

Bullish

Frequently Asked Questions About GNPX

Does GNPX pay dividends?: Genprex Inc (GNPX) does not currently pay a regular dividend.
What is GNPX's market cap?: Genprex Inc (GNPX) has a market capitalization of $3.01M with a current stock price of $3.71.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In